Screener
Bioventus BVS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | June 27, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $673,346 | $683,559 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $20,196 | $10,928 |
| Accrued liabilities | 109,361 | 130,242 |
| Current portion of long-term debt | 18,750 | 15,000 |
| Other current liabilities | 4,144 | 4,210 |
| Total current liabilities | 152,451 | 160,380 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's accounts payable?
- Bioventus (BVS) reported accounts payable of $20.2M in Q2 2026.
- How has Bioventus's accounts payable changed year-over-year?
- Bioventus's accounts payable decreased by 16.7% year-over-year, from $24.25M to $20.2M.
- What is the long-term trend for Bioventus's accounts payable?
- Over 5 years (2020 to 2025), Bioventus's accounts payable has grown at a 19.8% compound annual growth rate (CAGR), from $4.42M to $10.93M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Bioventus's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude